Gubra — Oktober 2024
-
Novo Nordisk kan stå over for mange fedmeudfordrere i 2029 https://proinvestor.com/investornyt/1226591/novo-nordisk-kan-sta-over-for-mange-fedmeudfordrere-i-2029
-
Status: Fremtiden for Novo Nordisk og de andre fedmeselskaber https://www.nordnet.dk/blog/novo-nordisk-sidste-nyt-fra-den-europaeiske-diabeteskonference-easd/?utm_source=ACS&utm_medium=email&utm_campaign=DK_nyhedsbrev_uge41_2024&fbclid=IwY2xjawF5g9hleHRuA2FlbQIxMQABHYhdr8AHTs1f_prdCsKh9-X7UTe9HMERheK7H8crDHdQgaFMKIZLzciwHA_aem_EviZJ9b_WZq88BfEExXoaw
-
OVERBLIK mandag d. 14/10-2023: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1226595/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Ny wegovy rekord i DK. Læs mere her https://proinvestor.com/boards/122569
-
skyldes det store fald utålmodige investorer, efter nordnets artikel om novo og andre fedmeselskaber?
-
Det gør det næppe Ulrik. Gubra tager løbende nogle pæne fald i perioder med lav omsætning og store spreads.
-
Spændende hvor bunden er i Gubra denne gang. Nogen som ved, hvornår man forventer nyheder om deres fase I-forsøg?
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1228314/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Der ser ikke ud til at være nogen bund i Gubra :-(.....håber snart på nyheder i form af deres fase I.
-
Stroka, haha ja, det har du da delvis ret i, men den er altså faldet fra toppen (754) til nu at ligge i 424, hvilket er et fald på 43-44%, så det "naturlige fald" behøver ikke at fortsætte
-
"Next year, Viking expects to file a request with the Food and Drug Administration to begin testing in people a drug that mimics the activity of hormones called amylin and calcitonin. Amylin helps control blood sugar while calcitonin regulates calcium levels in the blood". https://www.investors.com/news/technology/viking-therapeutics-stock-quad-eli-lilly-triple/?src=A00220
-
18% oppe i US pt.
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1234095/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim
Today Gubra announces that Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2) agonist BI 1820237 in obesity. No further information has been made available to Gubra.
The other three projects in the successful partnership with Boehringer remain unaffected and continue as planned. This includes the development of the potential ...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind